High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings.

Within the past dozen years, outbreaks of filoviral hemorrhagic fever within the human population have been occurring with increasing frequency, with an average of 1 epidemic now occurring every 1-2 years. Many of the outbreaks have been large (involving >150 cases), necessitating rapid responses from the international community to help implement infection control and surveillance. This increased activity, combined with today's climate of bioterrorism threats, has heightened the need for high-throughput methodologies for specific detection of these high-hazard viruses in sophisticated laboratory setups and mobile field laboratory situations. Using Zaire Ebola virus as an example, we describe here the development of a high-throughput protocol for RNA extraction and quantitative reverse-transcription polymerase chain reaction analysis that is safe, fast, and reliable. Furthermore, the applicability of this method to an outbreak setting was demonstrated by correct analysis of >500 specimens at a field laboratory established during a recent outbreak of Marburg hemorrhagic fever in Angola.

[1]  Christian Drosten,et al.  Rapid Detection and Quantification of RNA of Ebola and Marburg Viruses, Lassa Virus, Crimean-Congo Hemorrhagic Fever Virus, Rift Valley Fever Virus, Dengue Virus, and Yellow Fever Virus by Real-Time Reverse Transcription-PCR , 2002, Journal of Clinical Microbiology.

[2]  M. Bray Defense against filoviruses used as biological weapons. , 2003, Antiviral research.

[3]  Manfred Weidmann,et al.  Rapid detection protocol for filoviruses. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[4]  J. Strong,et al.  Laboratory diagnosis of Ebola and Marburg hemorrhagic fever. , 2005, Bulletin de la Societe de pathologie exotique.

[5]  R. Tesh,et al.  Rapid Molecular Strategy for Orbivirus Detection and Characterization , 2011, Journal of Clinical Microbiology.

[6]  Sina Bavari,et al.  The evolving field of biodefence: therapeutic developments and diagnostics , 2005, Nature Reviews Drug Discovery.

[7]  F. Kaducu,et al.  Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001. , 2001, MMWR. Morbidity and mortality weekly report.

[8]  Heinz Feldmann,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[9]  P. Jahrling,et al.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys , 2003, The Lancet.

[10]  P. Jahrling,et al.  ELISA for the detection of antibodies to Ebola viruses. , 1999, The Journal of infectious diseases.

[11]  J. A. Comer,et al.  Marburgvirus Genomics and Association with a Large Hemorrhagic Fever Outbreak in Angola , 2006, Journal of Virology.

[12]  H. Feldmann,et al.  MassTag Polymerase Chain Reaction for Differential Diagnosis of Viral Hemorrhagic Fevers , 2006, Emerging infectious diseases.

[13]  A. Sanchez,et al.  Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.

[14]  F. Omaswa,et al.  An outbreak of Ebola in Uganda , 2002, Tropical medicine & international health : TM & IH.

[15]  Stephen A. Bustin,et al.  A-Z of Quantitative PCR , 2004 .

[16]  A. Sanchez,et al.  Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. , 1999, The Journal of infectious diseases.

[17]  Jamie A. Blow,et al.  Virus inactivation by nucleic acid extraction reagents. , 2004, Journal of virological methods.

[18]  J. McCormick,et al.  Diagnosis of Ebola haemorrhagic fever by RT‐PCR in an epidemic setting , 2000, Journal of medical virology.

[19]  Stuart T. Nichol,et al.  Rapid Diagnosis of Ebola Hemorrhagic Fever by Reverse Transcription-PCR in an Outbreak Setting and Assessment of Patient Viral Load as a Predictor of Outcome , 2004, Journal of Virology.

[20]  B. Murphy,et al.  A Single Intranasal Inoculation with a Paramyxovirus-Vectored Vaccine Protects Guinea Pigs against a Lethal-Dose Ebola Virus Challenge , 2006, Journal of Virology.